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Outcome of different endovenous laser
wavelengths for great saphenous vein ablation
Lowell S. Kabnick, MD, FACS, Morristown and Newark, NJ
Objective: The objective of this randomized, prospective, blinded study was to determine the relative effects of two laser
wavelengths in the treatment of great saphenous vein (GSV) insufficiency.
Methods: Fifty-one male and female patients scheduled for routine laser treatment of GSV insufficiency provided signed
informed consent for the procedure. Patients were randomized to receive endovenous laser treatment with a wavelength
of 810 or 980 nm. The same surgeon, blinded to the wavelength, performed all procedures. Nonoperating study staff,
blinded to the laser wavelengths, evaluated patients before and after the procedure regarding physical signs and
symptoms. Patients were monitored within 72 hours after the procedure (via duplex ultrasonography), at 1 week (by
procedural site photos scored for bruising, as well as a pain score), at 3 weeks, and at 4 months for bruising, physical and
emotional effects of the procedure (scored by patients on a five-point visual analogue scale), and symptoms (scored by the
physician), along with adverse events. Patients were followed up for a year to determine the long-term efficacy of the
procedure.
Results: The 51 patients (38 women and 13 men; mean age, 52.4  11.7 years) completed treatment and follow-up
examination (30 legs for each wavelength). At 72 hours after the procedure, no significant differences were noted between
patient outcomes, physical conditions, and symptoms and or possible adverse events. At 1 week after the procedure,
bruising scores were significantly different (P < .005): patients in the 980-nm group showed less bruising of the
procedure site than the patients in the 810-nm group. Only three physical or symptom parameters presented with
significant differences (P < .05) over time—less itching was noted by 810 nm–treated patients at 3 weeks after the
procedure, lower levels of pain intensity were seen in the 980 nm–treated patients at the 4-month follow-up visit, and
lower varicose vein ratings were seen for the 980 nm–treated patients at the 4-month follow-up visit. Thirteen legs were
phlebitic at 7 days after the procedure (10 in the 810-nm group and 3 in the 980-nm group). Two treatment failures
occurred (one patient in each treatment group); both patients exhibited flow in the treated venous segment at the
4-month follow-up visit. Two other patients (one in each group) had treatment failure at the 1-year follow-up,
demonstrating venous insufficiency in the treated segment.
Conclusions: Both laser wavelengths were effective in treating GSV insufficiency, with no major complications and a
paucity of adverse outcomes. (J Vasc Surg 2006;43:88-93.)Traditional treatment for great saphenous venous
(GSV) insufficiency and resulting varicosities has involved
surgical ligation and stripping of the vessel segments. How-
ever, the associated morbidity and patient dissatisfaction
with the procedural results have led to the development of
alternative techniques for treating these vessels. Ambula-
tory phlebectomy and perforate invagination stripping
evolved to minimize the problems seen with traditional
surgical techniques.1,2 Nonsurgical techniques such as
ultrasound- and transcatheter-guided sclerotherapy, along
with radiofrequency ablation, have been developed as
options in the treatment of large-vessel varicosities.3-5 En-
dovenous laser therapy is one of the newest methods for
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vein, better cosmetic results, and no reduction in patient
mobility.6-9
Endovenous laser treatment involves placement of a
bare-tipped optical laser fiber inserted through a needle
puncture into an affected vein. The fiber is advanced
through the vein and placed accurately within the vessel
segment with the assistance of duplex ultrasound imaging.
The laser is turned on, and the fiber is slowly pulled back
through the vessel, thus allowing delivery of laser energy to
the vessel lumen to produce endothelial and venous wall
damage with subsequent fibrosis.
To date, there have been no published comparison
studies of the various laser wavelengths and their efficacy
in treating incompetent saphenous veins. Two wave-
lengths of lasers were selected for use in this investiga-
tion—810 and 980 nm—because of their differences in
characteristic absorption and their utility in the treat-
ment of saphenous venous insufficiency. The 810-nm
wavelength is specific for hemoglobin absorption, whereas
the 980-nm wavelength is specific for hemoglobin and
water. This article presents the findings of a blinded, ran-
domized investigation comparing the effects of 810- and
980-nm diode lasers in endovenous laser treatment of
saphenous venous insufficiency.
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Patients. Patients were consecutively selected individ-
uals awaiting surgery to treat GSV insufficiency at the Vein
Institute of New Jersey (Morristown, NJ) who had pro-
vided written informed consent before the procedure. Pa-
tients were informed that they would be randomized to one
of the two wavelengths of laser for the procedure and that
these were the typical wavelengths used for the treatment of
saphenous venous insufficiency at the institution and in the
USA. This study followed the principles as outlined in the
Declaration of Helsinki. All subjects gave informed con-
sent; the experimental protocol and informed consent were
approved by the Institutional Review Board.
Patients were eligible for treatment if they were at least
21 years of age, had symptomatic varicose veins and duplex
scan–determined GSV incompetence, and were willing to
return for all follow-up visits after the procedure. The
prestudy duplex examination evaluated the patient for su-
perficial venous insufficiency, superficial venous thrombo-
sis, deep venous insufficiency, deep venous thrombosis, and
measurement of the superficial veins of the GSV and the
small saphenous vein from groin to ankle. The duplex
examination also evaluated any other vascular tributary that
may have been insufficient (the anterior circumflex, for
example). Patients were excluded from study participation
if they had bleeding disorders, varicose veins without GSV
incompetence, or any other medical condition that would
not allow for safe completion of the surgical procedure.
Deep venous insufficiency was not an exclusion from study
participation, but deep venous thrombosis from popliteal
proximal was an exclusion factor.
Patients underwent a complete physical examination
before the procedure. All patients completed an evaluation
of involved limb pain before treatment by using a five-point
visual analogue scale on which 1 indicated no pain and 5
indicatedintensepain.Patients completedaphysical activity/
emotional survey to define the effects of their leg problems
on daily function (Fig 1, online only).
A staff nurse not associated with the study performed
the patient randomization; the nurse selected a blinded
randomization card (labeled for the intended wavelength
device) for each patient before the procedure. The blind
was broken, the patient was assigned to the specific treat-
ment group, and the surgical staff prepared the treatment
room with the appropriate laser. To blind the operating
physician to the equipment, the surgical lasers to be used in
the study were housed in identical cases, and all identifying
markings weremasked. AngioDynamics (Queensbury, NY)
provided the 980-nm laser used in the study, and biolitec,
Inc (East Longmeadow, MA) provided a Ceralas D 810-nm
laser for study use. Throughout the surgical procedure and
all patient follow-up examinations, the physician was
blinded to the patient’s treatment group. Once the study
was completed, the blind was broken for the collected data,
and the findings were analyzed.
Surgical technique. After providing written informed
consent for the procedure, the patient was brought to theprocedure room and placed supine on the surgical table.
The patient was draped in the usual sterile fashion. Local
anesthetic, consisting of approximately 150 to 200 mL of
0.25% lidocaine/epinephrine (buffered with 8.5% sodium
bicarbonate), was used to anesthetize the skin and provide
tumescent anesthesia localized to the saphenous compart-
ment.
Under ultrasound guidance, the GSV was accessed at
or below the knee area by using a 21-gauge micropuncture
catheterization set (AngioDynamics). Once the 5F micro-
sheath was inserted into the GSV, the distance from the
puncture site to the saphenofemoral junction was mea-
sured. The inner cannula from the microsheath was then
removed, and a 0.035-inch guidewire (AngioDynamics)
was advanced beyond the saphenofemoral junction into the
common femoral vein under direct ultrasound guidance
(Logic Book; General Electric,Milwaukee,WI). After a 45-
or 65-cm 5F sheath (AngioDynamics) was marked to indi-
cate the depth of anticipated penetration, the sheath was
backloaded onto the 0.035-inch wire and advanced
through the GSV to 1.5 cm below the saphenofemoral
junction or just distal to the epigastric vein. Once the
sheath was stabilized, the introducer and access wire were
removed, and a 600-m bare-tipped fiber (AngioDynam-
ics) was placed into the sheath. The aiming beam of the
laser fiber was then observed to the end of the sheath by
visual observation of the skin illumination and via ultra-
sonography (which had previously been placed in the de-
sired position). The sheath was withdrawn to the fiber’s
locking mechanism, thus exposing the laser fiber tip ap-
proximately 2.5 cm outside the sheath.
Under ultrasound guidance, dilute local anesthesia was
infused around the GSV along the entire segment to be
treated, by using 22- or 25-gauge needles. Approximately
150 to 200 mL of this solution was administered, thus
creating a 10-mm gap between the skin and the vein as well
as a 10-mm diameter around the vein (as verified by ultra-
sound examination). After modified tumescent anesthesia
was completed, the laser fiber final position was verified
with ultrasonography to confirm that the fiber tip had not
moved during anesthesia administration. Laser energy (10
W) was delivered in a continuous fashion through the vein
walls of the segment being treated, and the pullback speed
on the fiber was calculated to achieve a standard energy rate
of 50 J/cm. External manual compression was used only at
the level of the saphenofemoral junction, thus enabling the
physician to block heat transmission into this area. Manual
compression was performed by using the ultrasound probe
that had been placed in proper position. Once the entire
vessel segment had been treated with laser energy and was
confirmed to be closed (by duplex ultrasonography), the
catheter and laser fiber were removed, because no sclero-
therapy or phlebectomy procedures were performed with
the saphenous vein treatment. A½–inch Steri-Strip (3M, St
Paul, MN) cut into thirds was placed over the previous
entry puncture site and covered with a sterile 2  2-inch
gauze pad. A full-thigh class 2 compression stocking
(30-40 mm Hg) was then placed on the treated limb. The
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until bedtime the following evening. For the next 6 to 10
days, the patient was instructed to wear the stocking during
nonsleep hours only. No activity limitations were placed on
the patient except for restrictions against participation in
high-impact aerobics. All patients were also instructed to
take a nonsteroidal anti-inflammatory medication (cele-
coxib 200 mg/d) once daily for the first 10 days after the
procedure.
Clinical data collection. All patients were to return to
the clinic within 72 hours of the procedure, where they
each underwent a duplex ultrasound procedure to evaluate
flow in the treated vein, whether the treated vein was closed
and opened, and whether a thrombus was present. If a
thrombus was found, the duplex procedure would clarify
where it was located in relation to the saphenofemoral
junction. The patients returned to the office at the end of a
week for photographic documentation of the procedure
site and to determine a pain score. Photographs of the
procedure site were scored according to a bruising scale
from 0 (no visible bruising) to 5 (extreme bruising). The
patients were also scheduled to return to the clinic at 3
weeks and 4 months after the procedure for physical and
symptom evaluations.
At 72 hours, 3 weeks, and 4 months after the proce-
dure, all patients were to complete a survey of physical
activity (Fig 1, online only), and the physician documented
the patients’ current symptom status. Patient-measured
pain was documented with a visual analogue scale on which
1 indicated no pain and 5 indicated the worst pain ever felt.
Symptoms and physical signs evaluated by the physician
included pain, venous edema, inflammation, ulceration,
varicose veins, skin pigmentation, induration, the need for
compression therapy, fatigue, venous claudication, itching,
dermal sclerosis, and congestion (Fig 2, online only). Any
complications or adverse events that occurred from the day
of the procedure were documented. At 1 year after the
procedure, all patients were to return for a duplex exami-
nation of the vessel to determine whether the treated vessel
remained closed.
Statistical analysis. All demographic data were ana-
lyzed to determine the mean values for each laser group. An
analysis of variance was performed to evaluate all physical
activity and symptom survey parameters. Statistical signifi-
cance was defined as P  .05.
RESULTS
The patient groups were similar in age (51.1  11.3
years for the 810-nm group and 53.6  12.2 years for the
980-nm group) and sex distribution. Patients in each group
were similar in regard to their pretreatment symptoms and
physical signs at baseline. Patient CEAP scores for the leg
to be treated were very similar for these two populations
(2.03  0.62 for the 810-nm group and 2.23  0.63 for
the 980-nm group).
Nine of the 51 patients involved in the study had 2 legs
treated; of these patients, 9 legs were treated with the
810-nm laser, and 9 were treated with the 980-nm laser.Because of the randomization process, some of these pa-
tients had both legs treated with the same wavelength laser,
whereas others had one leg treated with the 810-nm laser
and one leg treated with the 980-nm laser. Because so few
study patients were treated bilaterally, statistical analysis of
this subset was not performed.
Thirteen patients presented with phlebitis at 1 week
after the procedure (10 patients in the 810-nm group and 3
in the 980-nm group): phlebitis was defined as induration,
erythema, pain to palpation, and a palpable cord. The differ-
ences in the amount of laser energy used and the specifics of
the treatment of these patients vs the patients who did not
develop phlebitis are presented in Table I. A subset analysis
(performed at 1 week after the procedure) of postproce-
dural symptoms and physical condition parameters for pa-
tients who presented with clinical superficial phlebitis indi-
cated that patient-graded pain scores were significantly
increased compared with patients who did not have phle-
bitis after the procedure. When questioned by using a visual
analogue pain score of 0 to 10 (0, no effect; 10, worst pain
ever), these patients on average graded their pain at 5.0,
whereas patients without phlebitis graded their pain at 2.5.
At 72 hours after the procedure, no significant differences
between the study groups were noted for any of the patient
symptoms or physical condition parameters (as shown in
Figs 1 and 2, online only) or for procedural outcomes. By 7
days after the procedure, bruising scores (Table II) were
significantly different between treatment groups (P 
.0047), with less bruising noted for the 980-nm group
compared with the 810-nm group. After surgery, only
three physical or symptom parameters had significant dif-
ferences over time when the groups were compared (Table
III). Itching was significantly lessened at 3 weeks after the
procedure for the 810-nm group compared with the
980-nm group (P  .031), but this difference was not
Table I. Procedural details
Variable
810-nm-
wavelength
laser (30 limbs)
980-nm-
wavelength
laser (30 limbs)
No. limbs treated 30 30
Phlebitis 10 3
No phlebitis 20 27
CEAP score
Mean (SD) 2.03 (0.62) 2.23 (0.63)
Range 0-4 1-4
Treated vein diameter
No phlebitis (mm) 9.39 8.72
Phlebitis (mm) 10.59 11.96
Energy used
All vessels (J/cm) 49.25 45.92
No phlebitis (J/cm) 49.99 44.73
Phlebitis (J/cm) 50.00 56.66
Pullback speed
All vessels (cm/min) 16.03 17.51
No phlebitis (cm/min) 15.96 17.54
Phlebitis (cm/min) 16.10 12.61maintained at the 4-month visit. Postprocedural pain inten-
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pared with the 810-nm group at the 4-month follow-up
visit (P .028). The varicose vein rating was significantly
lower (thus indicating a decrease in visible varicosities) in
the 980-nm group vs the 810-nm group at the 4-month
Table II. Patient bruising scores* at 1 week after the proc
Variable 810-nm-wavelen
All patients 2.40 (30
No phlebitis 2.40 (20
Phlebitis 2.40 (10
Data are mean (number of patients).
*Bruising scores were based on a five-point grading system where 0 indicat
†P .0047. Patient subsets were not analyzed for statistical significance.
Score  0 Sco
Table III. Postprocedural differences in symptoms and
physical condition
Variable
810-nm-
wavelength
laser
980-nm-
wavelength
laser P value
Itching
72 h 0.467 (30) 0.433 (30) .872
3 wk 0.167 (30) 0.500 (30) .031*
4 mo 0.033 (30) 0.034 (29) .981
Pain intensity
72 h 2.63 (30) 2.20 (30) .081
3 wk 2.10 (30) 2.07 (30) .891
4 mo 1.50 (30) 1.21 (30) .028*
Varicose vein rating
72 h 1.60 (30) 1.43 (30) .325
3 wk 1.50 (30) 1.27 (30) .194
4 mo 0.97 (30) 0.31 (29) .00*
Data are mean (number of patients).
*P values determined with analysis of variance, where P.05 was defined as
statistically significant.follow-up visit (P  .004). The remaining parameters(defined in Figs 1 and 2, online only) did not show signif-
icant differences between groups (Table IV).
There was an overall lack of postprocedural complica-
tions in both patient populations. However, there were
four treatment failures in this study population (two pa-
tients in each treatment group); all patients with treatment
failure exhibited a return of flow in the treated segment of
the GSV by their 1-year follow-up visits, and reflux was
noted after limb compression and release. The remaining
56 treated legs remained flow free at 1 year after the
procedure and were defined according to the protocol as
treatment successes.
DISCUSSION
The primary aim in the treatment of saphenous vein
insufficiency should be directed toward identification of the
highest level of reflux and ablation of the incompetent
venous segment. Although surgical ligation and stripping
have been used successfully in the past, the current trend
toward the endovenous laser technique has shown that
patients respond well to the procedure and that the incom-
petent venous sections can be treated readily.
Gerard et al10 and Oh et al9 detailed their findings with
the 980-nm diode laser. They found complete occlusion
and retraction of the GSV over the postoperative period (4
e
ser 980-nm-wavelength laser
1.55 (30)†
1.39 (27)
3.00 (3)
visible bruising and 5 indicates extreme bruising, as shown below.
2 Score  5edur
gth la
)
)
)
es no
re and 12 weeks, respectively). Proebstle et al11 have shown
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Variable
Laser
wavelength (nm)
Before the
procedure
After the
procedure (at 4 mo) P value*
Physical and emotional parameters (patient generated)
Intensity of pain 810 2.37 1.50 .005
980 1.90 1.21 .005
Limitations because of leg 810 2.23 1.47 .005
980 2.13 1.38 .005
Sleep lost 810 1.77 1.20 .005
980 1.63 1.24 .037
Limits of standing 810 2.60 1.83 .005
980 2.73 1.48 .005
Limits of stairs 810 1.93 1.53 .072
980 1.60 1.38 .215
Crouching/kneeling 810 2.47 1.57 .005
980 1.90 1.38 .014
Walking briskly 810 2.10 1.40 .005
980 1.80 1.34 .055
Travel 810 2.10 1.20 .005
980 2.13 1.10 .005
Housework 810 1.97 1.40 .005
980 1.67 1.24 .011
Social functions 810 2.00 1.33 .011
980 1.97 1.10 .005
Sporting activities 810 2.20 1.67 .023
980 2.23 1.62 .023
Feel on edge 810 1.87 1.37 .050
980 2.67 1.41 .005
Tired quickly 810 2.43 1.67 .009
980 2.30 1.52 .009
Burden 810 1.23 1.23 —
980 1.47 1.07 .057
Precautions 810 2.40 1.87 .063
980 2.67 1.59 .005
Embarrassed 810 3.30 2.47 .024
980 3.80 2.48 .005
Irritated 810 1.70 1.30 .122
980 2.20 1.48 .024
Handicapped 810 1.43 1.17 .296
980 1.83 1.14 .006
Difficulty in the morning 810 1.73 1.33 .141
980 1.77 1.17 .019
Don’t feel like going out 810 1.40 1.20 .408
980 1.77 1.14 .009
Physical symptoms (physician generated)
Pain 810 1.33 0.37 .005
980 1.13 0.17 .005
Venous edema 810 0.97 0.03 .005
980 0.80 0.10 .005
Inflammation 810 0.50 0.03 .005
980 0.23 0.00 .049
Varicose veins 810 2.03 0.97 .005
980 2.03 0.31 .005
Pigmentation 810 0.20 0.13 .339
980 0.47 0.07 .038
Induration 810 0.20 0.00 .105
980 0.40 0.00 .011
Compression 810 0.80 1.17 .157
980 0.67 1.45 .005
Fatigue 810 1.10 0.13 .005
980 0.73 0.17 .005
Venous claudication 810 0.03 0.00 .321
980 0.27 0.00 .008
Itching 810 0.23 0.03 .046
980 0.50 0.03 .005
Dermal sclerosis 810 0.03 0.00 .321
980 0.00 0.00 —
Congestion 810 0.67 0.07 .005
980 0.67 0.03 .005*P value for analysis of variance of preprocedure vs 4-month findings, where significance was defined as P .05.
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ciency of the lesser saphenous vein, with a 6-month
follow-up showing no recanalization of the vessel. Min and
associates’12 long-term follow-up study showed that 93.4%
of the limbs treated with the 810-nm endovenous laser
remained closed at 2 years after the procedure, and this rate
is similar to the 93.3% (28/30 limbs) success seen in our
study at 1 year. Fifty percent (two of four) of our treatment
failures were noted by the 4-month follow-up visit, the
remaining two cases were seen at the 1-year follow-up visit.
Gerard and colleagues’10 short-term follow-up of patients
treated with the 980-nm endovenous laser showed a 90%
success rate at 1 month after the procedure, compared with
the 93.3% (26/30 limbs) success seen in our study at 1 year
after treatment. The results from our blinded comparison
of these two wavelengths of endovenous laser seem consis-
tent with, if not slightly better than, the success rates shown
in previous studies.
The overall physical and symptom findings after treat-
ment seemed very similar for our two device groups, with
significant findings seen at the short-term (more bruising at
1 week after surgery for the 810-nm group) that did not
seem to affect patient recovery over the longer term. This
level of bruising may be related to one of two factors:
anesthesia administration or perforation caused by the laser
energy. Administration of anesthesia by intravenous injec-
tion could lead to some escape of blood into the surround-
ing soft tissue, with subsequent bruising. Laser energy
applied in a pulsing mode has been shown to lead rarely to
perforation of the vein wall, as discussed by Weiss.13 In our
institutional experience, laser energy delivered in a contin-
uous mode is less disruptive of the vessel wall.
When comparing physical findings, only itching, post-
procedural pain, and varicose vein ratings were significantly
different between groups; however, these differences were
seen only at single time points during follow-up and did not
lead to complications or the need for further treatment. It is
possible that these differences may be due to unexamined
concomitant disease (for example, deep venous insuffi-
ciency), but further investigation into the effects on post-
operative pain intensity needs to be pursued.
Overall, the results of this study showed that both the
810- and 980-nm laser wavelengths were effective in clos-
ing the GSV with a reflux-free saphenofemoral junction.
Few untoward results were found with either treatment; no
deep venous thrombosis (confirmed by ultrasound exami-
nation), pulmonary embolism, skin burns, or paresthesias
were reported. Some ecchymosis was seen, and superficial
phlebitis was more often present when the 810-nm laser
was used. However, the pain noted after the procedure was
most likely related to superficial phlebitis and not to the
ecchymosis.14
CONCLUSION
The results of this study reveal some positive trending
differences in favor of the 980-nm wavelength laser; therewere more untoward results with the 810-nm wavelength.
Both lasers seemed safe and effective for the treatment of
GSV insufficiency.
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Fig 2. Physician’s symptom assessment.
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1. What was the intensity of pain in the ankles or legs?  
2. To what extent did you feel bothered/limited in your work or other daily 
activities because of your leg problems? 
3. Did you sleep badly because of your leg problems? 
4. To what extent did your leg problems bother/limit you while doing the 
following movements or activities: 
-  Standing for a long time 
-  Climbing stairs 
-  Crouching, kneeling 
-  Walking briskly 
-  Travel by car, bus, plane 
-  Housework such as working in the kitchen, carrying a child, ironing, 
cleaning floors or furniture, doing handy work 
-  Social functions, such as weddings, parties, restaurants, night clubs 
-  Sporting activities, making physically strenuous efforts 
Emotional parameters: 
1. I feel on edge 
2. I become tired quickly 
3. I feel I am a burden to people 
4. I must always take precautions 
5. I am embarrassed to show my legs 
6. I get irritated easily 
7. I feel handicapped 
8. I have difficulty getting going in the morning 
9. I do not feel like going out 
[Patients used a 5-point visual analog scale, where 1 = absence of condition, 
annoyance, or limitation and 5 = greatest intensity.] 
Fig 1. Patient survey.Venous Clinical Severity Score*: 
1. Pain  
2. Venous edema 
3. Inflammation 
4. Number of active ulcers 
5. Active ulcers, size 
6. Active ulcers, duration 
7. Varicose veins 
8. Skin pigmentation 
9. Induration 
10. Compressive therapy 
Other Symptoms: 
1. Fatigue 
2. Venous claudication 
3. Itching 
4. Dermal sclerosis 
5. Congestion sensation 
[Physician used a 4-point scale, ranging: absent – mild – moderate – severe.] 
* Based on the scoring system presented by Rutherford et al [14].  
